SCHEMBL2541491

SCHEMBL2541491

Nc1ccc(N=Nc2ccc(-c3ccc(O)cc3)cc2)c2ccc(S(=O)(=O)O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 1.00
▸ CYP2C19 P33261 1/20 1.00
▸ HSD17B10 Q99714 1/20 1.00
▸ PHLPP2 Q6ZVD8 2/20 0.80
▸ SLC7A11 Q9UPY5 1/20 0.62
▸ SENP3 Q9H4L4 6/20 0.57
▸ SENP2 Q9HC62 6/20 0.57
▸ SENP1 Q9P0U3 6/20 0.57
▸ SUMO2 P61956 4/20 0.57
▸ SUMO1 P63165 4/20 0.57
▸ SENP7 Q9BQF6 4/20 0.57
▸ GLO1 Q04760 5/20 0.55
▸ ENPP2 Q13822 1/20 0.52
▸ MEN1 O00255 2/20 0.45
▸ THRB P10828 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ TDP1 Q9NUW8 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ APP P05067 1/20 0.45
▸ MAPT P10636 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2541489 1.00 CYP2C9 (1.00) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL14418368 0.95 CYP2C9 (0.90) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL14413264 0.94 CYP2C9 (0.88) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2585430 0.90 CYP2C9 (0.81) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2585427 0.90 CYP2C9 (0.81) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12224760 0.89 PHLPP2 (1.00) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12177913 0.89 CYP2C9 (0.79) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12177898 0.86 CYP2C9 (0.76) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL12177917 0.86 CYP2C9 (0.75) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11
SCHEMBL2587653 0.85 CYP2C9 (0.73) CYP2C9CYP2C19HSD17B10PHLPP2SLC7A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-04-16 — — US claimed
US-20240167107-A1 COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION APTITUDE MEDICAL SYSTEMS, INC. (US) 2024-05-23 — — US claimed
US-20240165143-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO EMORY UNIVERSITY 2024-05-23 — — US claimed
CN-114867351-B 4' -Halogen-containing nucleotide and nucleoside therapeutic compositions and related uses 埃默里大学 2024-04-23 — — CN claimed
WO-2022177842-A1 COMPOSITION AND METHOD FOR NUCLEIC ACID DETECTION APTITUDE MEDICAL SYSTEMS, INC (US) 2022-08-25 — — WO claimed
EP-4040965-A2 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO Emory University (US) 2022-08-17 — — EP claimed
CN-114867351-A 4' -halo-containing nucleotide and nucleoside therapeutic compositions and uses related thereto 埃默里大学 2022-08-05 — — CN claimed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US claimed
WO-2005083081-A1 IMPROVED NUCLEASE INHIBITOR COCKTAIL AMBION, INC. (US) 2005-09-09 — — WO claimed
US-20050014169-A1 Nuclease inhibitor cocktail AMBION, INC. 2005-01-20 — — US claimed
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO UNIV EMORY (US) 2026-04-16 — — US disclosed
EP-4714452-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS Gilead Sciences, Inc. (US) 2026-03-25 — — EP disclosed
EP-4638789-A1 METHODS FOR TETHERING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES 10X Genomics, Inc. (US) 2025-10-29 — — EP disclosed
WO-2025111463-A1 METHODS FOR PROCESSING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES 10X GENOMICS, INC. (US) 2025-05-30 — — WO disclosed
US-20250163502-A1 METHODS FOR PROCESSING RIBONUCLEIC ACIDS IN BIOLOGICAL SAMPLES 10X GENOMICS, INC. 2025-05-22 — — US disclosed
US-7264932-B2 Nuclease inhibitor cocktail APPLERA CORPORATION (US) 2007-09-04 — — US disclosed
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same AMBION, INC (US) 2007-02-08 — — US disclosed
WO-2005083081-A1 IMPROVED NUCLEASE INHIBITOR COCKTAIL AMBION, INC. (US) 2005-09-09 — — WO disclosed
US-20050014169-A1 Nuclease inhibitor cocktail AMBION, INC. 2005-01-20 — — US disclosed
WO-2004076640-A2 SMALL-MOLECULE INHIBITORS OF ANGIOGENIN AND RNASES AND IN VIVO AND IN VITRO METHODS OF USING SAME AMBION, INC. (US) 2004-09-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102422-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO SARS1, ITK, SLC43A1 CYP2C9 1897/4885CYP2C19 2363/4885HSD17B10 3044/4885
US-20070032418-A1 Small-molecule inhibitors of angiogenin and rnases and in vivo and in vitro methods of using same RNASE1, RNASEH1, RNASEL CYP2C9 4801/4885CYP2C19 4749/4885HSD17B10 2691/4885
US-20240165143-A1 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO PNP, PRPF4, HPRT1 CYP2C9 3021/4885CYP2C19 2813/4885HSD17B10 4293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback